SURYA PHARMACEUTICAL LTD.

NSE : NABSE : 532516ISIN CODE : INE249G01020Industry : Pharmaceuticals & DrugsHouse : Private
BSE0.160 (0 %)
PREV CLOSE ( ) 0.16
OPEN PRICE ( ) 0.16
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.16 (749508)
VOLUME 234695
TODAY'S LOW / HIGH ( )0.16 0.16
52 WK LOW / HIGH ( ) 0.160.16
NSE
This Company is not listed in NSE
( in Million)
Select year
ParticularsMar2013Mar2012Mar2011Mar2010
Profit Before Tax-3326.78-4329.841227.89881.42
Adjustment2889.122133.921283.50741.28
Changes In working Capital3032.336046.27-1629.0085.62
Cash Flow after changes in Working Capital2594.673850.36882.391708.33
Cash Flow from Operating Activities1332.063656.75720.991627.72
Cash Flow from Investing Activities-79.49-1799.07-2702.28-1482.95
Cash Flow from Financing Activities-1331.16-1858.681948.76-37.90
Net Cash Inflow / Outflow-78.59-1.00-32.52106.86
Opening Cash & Cash Equivalents159.91160.91193.4486.57
Cash & Cash Equivalent on Amalgamation / Take over / MergerNANANANA
Cash & Cash Equivalent of Subsidiaries under liquidationsNANANANA
Translation adjustment on reserves / op cash balalces frgn subsidiariesNANANANA
Effect of Foreign Exchange FluctuationsNANANANA
Closing Cash & Cash Equivalent81.32159.91160.91193.44

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.